StemCell Therapy

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1702.89 mn during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The presence of a large patient pool has been instrumental in driving the growth of the market.

Neuropathy Pain Treatment Market 2020-2024 : Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024 : Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our neuropathy pain treatment market report covers the following areas:

This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Neuropathy Pain Treatment Market 2020-2024 : Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the neuropathy pain treatment market, including some of the vendors such as Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi Backed with competitive intelligence and benchmarking, our research reports on the neuropathy pain treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024 : Key Highlights

Table Of Contents :

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by Drug Class

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read this article:
Research Report with COVID-19 Forecasts - Neuropathy Pain Treatment Market 2020-2024 | Presence Of Large Patient Pool To Boost Growth | Technavio -...

The Global Diabetic Neuropathy Market 2020 Research Report is a professional and in-depth study on the current state of Diabetic Neuropathy Market.

This is the latest report, covering the current COVID-19 impact on theDiabetic Neuropathy market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides the latest insights about the Diabetic Neuropathy market drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

Click here to get the short-term and long-term impact of COVID-19 on this Market:https://marketresearch.biz/report/diabetic-neuropathy-market/covid-19-impact

The Diabetic Neuropathy Market Report Covers the Following Companies:

Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc, Cephalon Inc, Meda Pharma GmbH, GlaxoSmithKline plc, NeuroMetrix Inc, Johnson & Johnson Inc, Boehringer Ingelheim GmbH, Astellas Pharma Inc

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants to understand the competitive scenario to plan future strategies.

For Better Understanding, Download FREE Sample PDF Copy of Diabetic Neuropathy Market Research Report :https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

The Report Provides:

An overview of the Diabetic Neuropathy market

Current COVID-19 impact on the Diabetic Neuropathy market

Comprehensive analysis of the market

Analyses of recent developments in the market

Events in the market scenario in the past few years

Emerging market segments and regional markets

Segmentations up to the second and/or third level

Historical, current, and estimated market size in terms of value and volume

Competitive analysis, with company overview, products, revenue, and strategies.

An impartial assessment of the market

Strategic recommendations to help companies increase their market presence

Download FREE Sample PDF Copy Now!

The Diabetic Neuropathy Market Report Addresses the Following Queries:

What is the estimated size of the market by 2029?

Which segment accounted or a large share of the market in the past?

Which segment is expected to account the largest market share by 2029?

Which governing bodies have approved the use of Diabetic Neuropathy?

Which region accounts for a dominant share of the market?

Which region is anticipated to create lucrative opportunities in the market?

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

Europe (Germany, the UK, France, and Rest of Europe)

North America (the US, Mexico, and Canada)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (GCC Countries and Rest of the Middle East & Africa)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

Contact Us

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Read the original here:
Diabetic Neuropathy Market All-Inclusive Research Report 2020 : Includes Impact of COVID-19 On Market - Cole of Duty

Newswise BOSTON - Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

The American Association for Cancer Research (AACR) announced that in partnership with the Lung Cancer Initiative at Johnson & Johnson (LCI) it will award $1 million dollars to a multi-institutional team focused on developing digital tools to engage high-risk smokers in an innovative smoking cessation program designed to encourage behaviors that promote lung health.

This team project is co-led by Dana-Farber nurse-scientist Mary E. Cooley, PhD, RN, FAAN, whose research arose out of her experience as an advanced practice nurse working as part of a multidisciplinary team focused on treating and supporting lung cancer patients and their families. Smoking cessation, even after the diagnosis of lung cancer, is essential to improving clinical outcomes, said Cooley. Our hope is this program encourages behaviors that promote lung health and early lung cancer detection. The other co-leaders are Peter Castaldi, MD, MSC, assistant professor of medicine at Harvard Medical School and Sun S. Kim, PhD, associate professor of nursing at the University of Massachusetts.

A separate research project recently received funding from the National Institutes of Health (NIH) to study chemotherapy-induced peripheral neuropathy. The study, led by Dana-Farber nurse-scientist Robert Knoerl, PhD, RN, looks at metabolomic and genetic markers of neuropathy in adolescents and young adults with cancer.

Essentially theres only one first-line treatment for neuropathy, said Knoerl. One reason for the lack of effective treatments is that we dont understand the underlying causes of neuropathy. We hope with this study to identify potential biomarkers that can be targeted in the future.

The mission of the Cantor Center is to reduce the burden of cancer through scholarly inquiry and rigorous research. The focus of the Centers research is the patient/family experience of living with cancer, as well as survivorship issues post-treatment.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the worlds leading centers of cancer research and treatment. It is ranked in the top 5 of U.S. News and World Reports Best Hospitals for both adult and pediatric cancer care. Dana-Farbers mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

Go here to read the rest:
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants - Newswise

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.

After every treatment at Women & Infants Hospital in Providence, Rhode Island, the 15-year survivor of ovarian cancer adds sparkling creations to an earring tree placed there by volunteers. Patients are free to choose from and keep the jewelry that hangs there.

Dziobek also gives away jewelry when shes treated at Dana-Farber Cancer Institute in Boston. She has made rings for patients whose swollen fingers are too large for standard sizes and instructed others in bracelet-making techniques.

It makes people feel good and doing something productive while Im here gives me purpose, Dziobek, a retired nurse, says. A couple of months ago, a woman told me that my blue earrings were the only ones she could find that matched her dress for her daughters wedding. She was in the middle of her treatment and had no hair, but she had a beautiful scarf with the earrings to match her dress. It really helped, and she couldnt thank me enough. I had tears in my eyes; it was like a connection was made. You dont realize the impact you have when you do something like this.

Dziobek picked up her hobby in 2010 and was taking classes at a bead store when she experienced a recurrence of her cancer, first diagnosed in 2004. After radiation, she joined a clinical trial of intraperitoneal chemotherapy plus the targeted drug Velcade (bortezomib), but complications arose after one treatment, and she needed surgery. That was followed by six months of intravenous chemotherapy.

While recovering, Dziobek periodically reflected on a cuff bracelet shed begun before treatment. Although she was not sure if she would be able to follow the directions or do the intricate beading work due to her brain fog and neuropathy, she returned to her project. It took her three months to finish.

It helped me to focus, and I started to come out of the fog of chemo brain and my hands felt better, she recalls.

I felt like I was creating new pathways in my brain by focusing and figuring out color palette, placement of beads and measurements.

Dziobek was still part of the beading group, and her fellow members decided to help other patients enjoy a similar experience. They developed the Plum Blossom Project, bringing beaders to cancer centers to instruct patients in making bracelets. After completing a piece, each patient was gifted a beaded necklace made by volunteers. Dziobeks husband, Joe, helped raise funds for the project by selling CDs of two songs he wrote and performed, one about Plum Blossom and the other about the caregivers journey (youtube. com/watch?v=cd3DotLtwrE).

The group recently stopped working with patients who have cancer, but a few years ago Dziobek invited members to give a class for the gynecologic cancers support group at Women & Infants, where she goes twice a week for magnesium infusions to treat a long-term side effect of chemotherapy.

It made a difference for participants, especially one woman and her daughter.

The mom, who had been in treatment all day, wanted to take the class, but the daughter was burnt out and wanted to get home, Dziobek recalls. In the 15 to 20 minutes that they were selecting beads and putting their bracelets together, we could see the daughters shoulders and facial muscles relax, and the conversation changed. By the time they left, rather than a stressed-out caregiver taking care of a relative, it was now a mother-daughter relationship. They were excited about the bracelets theyd made, and their whole demeanor changed.Their story is a reminder, Dziobek says, of the importance of finding something enjoyable to do during cancer treatment, an idea she keeps front of mind as she prepares to enter a clinical trial at Dana-Farber.

Treatment really wears you down and the toll is cumulative, but if theres something you can do to help yourself at least feel a little better, do it, suggests Dziobek, who also finds meaning by volunteering with the Partnership to Reduce Cancer in Rhode Island, a community advisory group that works with the state health departments comprehensive cancer control program.

The partnership holds an annual June cancer summit, for which Dziobek is planning a survivor-led presentation to show participants how to make meditation bracelets and emphasize the health benefits of beading.

I firmly believe that we have to have some purpose each day and something to look forward to, no matter how we feel, she says. It continues to give you hope and keeps you moving forward.

See the original post:
Finding Meaning While Waiting in the Infusion Chair - Curetoday.com

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

- Data continue to support a NaPi2b biomarker-based patient selection strategy

- Generally well-tolerated with no new safety signals

- Data to be presented on a conference call today at 8 a.m. ET and at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma.The Company will host a conference call and webcast today,Wednesday, May 27, 2020, at8:00 a.m. ETduring which investigatorDebra L. Richardson, MD, Associate Professor of Gynecologic Oncology at theStephenson Cancer Centerat theUniversity of Oklahoma Health Sciences Centerand theSarah Cannon Research Instituteand members of the Mersana executive team will present and discuss these data. These data will also be presented in a poster session at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020 starting at 8:00 a.m. ET.

These data demonstrate not only that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, can deliver confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer, but also that these responses can deepen over time in a patient population with poor prognosis and limited treatment options, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. XMT-1536 continues to demonstrate that it is generally well tolerated, without the dose-limiting toxicities of other ADC platforms such as severe neutropenia, neuropathy and ocular toxicity. These are encouraging signals as we look forward to reporting more mature data in the second half of the year and continuing to advance XMT-1536 for both platinum-resistant ovarian cancer and NSCLC adenocarcinoma patients.

The expansion portion of the Phase 1 study is enrolling patients with platinum-resistant ovarian cancer, fallopian tube or primary peritoneal cancer who have received up to three lines of prior therapy and in some cases four lines of prior therapy regardless of platinum status as well as patients with NSCLC adenocarcinoma who had received prior treatment with platinum-based therapy and immunotherapy or targeted agents. With a data cutoff of May 1, 2020 these data include 34 patients total, 27 with ovarian cancer and seven with NSCLC adenocarcinoma. Patients with ovarian cancer had a median of three prior lines of treatment (range 1-5), and patients with NSCLC adenocarcinoma had a median of two lines of therapy (range 1-3).Fifteen of the patients were dosed at 36 mg/m2, and 19 patients were dosed at 43 mg/m2 every four weeks. Key findings include:

*7 patients not evaluable: 1 withdrew consent (Lower NaPi2b Expression); 1 with unrelated SAE leading to discontinuation and death (Lower NaPi2b Expression); 5 have not yet received a scan**uPR=1 patient with unconfirmed PR; confirmatory scan pending at the time of data cutHigher NaPi2b Expression: defined in dose escalation as at / above lowest H-score at which response observed (110)Lower NaPi2b Expression: defined in dose escalation as below the lowest H-score at which response observed (<110)

Conference Call DetailsMersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET during which investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute and members of the Mersana executive team will present and discuss these data. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7785868. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at http://www.mersana.com.

About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanas second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanas customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials and expectations regarding future clinical results based on data achieved to date. Forward-looking statements generally can be identified by terms such as aims, anticipates, believes, contemplates, continues, could, estimates, expects, goal, intends, may, on track, plans, possible, potential, predicts, projects, seeks, should, target, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later clinical trials, and that the development and testing of the Companys product candidates will take longer and/or cost more than planned, as well as those listed in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020, the Companys Quarterly Report on Form 10-Q filed with the SEC on May 8, 2020 and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic might adversely affect the Companys preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Companys operations and the value of and market for the Companys common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contact:

Investor & Media ContactSarah Carmody617-844-8577scarmody@mersana.com

Here is the original post:
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study - GlobeNewswire

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

What the report encloses for the readers:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Liquid Chromatographymass Spectroscopy MarketLiquid Chromatography-Mass Spectroscopy Segmented By Triple Quadrupole, Time of Flight, Quadrupole Technology in Clinical Testing, Environmental Testing, Forensic Testing.For More Information

Biopharmaceutical MarketBiopharmaceuticals Market Segmented By Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor, Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins Type for Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
Neuropathic Pain Market to Witness CAGR 5.6% Growth in Revenue During the Period 2024 - WaterCloud News

THE WOODLANDS, TX - A number of Houstons aging residents are turning to non-invasive regenerative therapies to get relief from chronic pain associated with degenerative conditions like osteoarthritis, neuropathy, back and joint pain.

Doctors Jeffery Pruski, D.C., and Edward Nash, M.D., are pain management and regenerative medicine specialists at 3R Regenerative Repair & Relief (3R), located just outside of Houston in The Woodlands, Texas. Over the past three years, the doctors have seen a steady rise in patients over the age of 55 looking for alternatives to knee replacements, back surgeries, and opioid pain medications to relieve chronic pain.

As we age, the body loses its natural ability to heal itself, said Dr. Pruski. Unlike traditional pain management, which typically treats the symptoms of the pain with surgery or medications, regenerative therapies treat the root cause of the pain. It creates a healing environment inside the joint, or area of degeneration, that uses the bodys own healing capacity to regenerate healthy cells and restore normal function to damaged areas.

Older adults are more likely to experience chronic pain conditions like osteoarthritis, cancer, neuropathies and osteoporotic-related fractures.

Dr. Pruski believes more seniors are choosing regenerative therapies over traditional treatments out of concerns with taking opioid medications and because, compared to surgery, there is no trauma to the body, no anesthesia, no cutting of the skin or foreign implants; all of which pose additional health risks to one of our most vulnerable populations.

Roughly 60% of the patients treated at 3R are 55 or older. Doctors Pruski and Nash use a combination of non-invasive modalities approved by the FDA, including physical therapy, chiropractic care, regenerative medicine and biological therapy to help aging patients relieve pain and inflammation, speed recovery of injured or damaged areas, and improve their quality of life.

Dr. Pruski said while treatments vary for each individual patient, the doctors at 3R are seeing very successful outcomes treating aging patients suffering from chronic pain with the use of advanced technologies and interventions such as Regenerative Injection Therapies, Pulsed Electromagnetic Field (PEMF) therapies and Hako-Med therapy, which stimulates the nerves to provide muscle re-education and pain relief for a variety of degenerative joint conditions and nerve problems, along with muscle work, massage therapy and home exercise.

Our entire focus is preventative and regenerative care so that patients of all ages and all activity levels can maintain a healthy, pain-free life, said Dr. Pruski. We see everyone from professional and retired pro athletes, to everyday people who just want to be able to pick up their grandkids or make themselves a cup of coffee without pain. Todays technology allows us to accomplish healing and pain management goals for all of our patients in the most pain-free, non-invasive way possible. Most treatments last less than 30 minutes, require nothing more than a Band-Aid, with no recovery or down time, and you can drive yourself home.

Most insurance companies cover the majority of treatments at 3R Regenerative Repair & Relief, however coverage for biologic injection procedures may vary from policy to policy.

For more information on services and telemedicine consultations at 3R please visit https://www.3RRegenerativeMedicine.com.

See the original post:
Regenerative Therapies Helping Houston Seniors Find Non-Surgical Relief from Chronic Pain, Arthritis at Woodlands Clinic - Woodlands Online

SEATTLE, May 25, 2020 (GLOBE NEWSWIRE) -- Various lesions or diseases of the somatosensory system may lead to neuropathic pain. Nerve blockage and pharmacological remedies are used in the treatment and management of neuropathic pain.

The global neuropathic pain market is estimated to account for US$ 9,862.3 Mn in terms of value by the end of 2027.

Market Drivers:

High prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Market Opportunities:

R&D in neuropathic pain is expected to offer lucrative growth opportunities for players in the market. For instance, in May 2020, researchers from University Medical Center Hamburg-Eppendorf and other prominent universities in Germany reported that loss of C-fiber may lead to neuropathic pain in Schwannomatosis, a form of neurofibromatosis caused due to the occurrence of multiple schwannomas, tumors that develops from the Schwann cells.

Moreover, adoption of nanoparticles in therapies is also expected to aid in growth of the global neuropathic pain market. For instance, in May 2020, researchers from Chungnam National University Hospital, South Korea, reported that poly(D,L-lactic-co-glycolic acid)-encapsulated CX3CR1 small interfering RNAs nanoparticles may aid in the treatment of neuropathic pain.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3656

Key Takeaways:

The global neuropathic pain market was valued at US$ 6,313.4 Mn in 2019 and is forecast to reach US$ 9,862.3 Mn by 2027 at a CAGR of 5.6% between 2020 and 2027. Increasing prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period.

Anticonvulsants segment held dominant position in the global neuropathic pain market in 2019, accounting for 40.8% share in terms of value. Development of new drugs for the treatment of neuropathic pain is expected to drive the segment growth.

Diabetic neuropathy segment held dominant position in the global neuropathic pain market in 2019, accounting for 46.4% share in terms of value, followed by Chemotherapy-induced peripheral neuropathy and others, respectively. Increasing prevalence of diabetic neuropathy in developing economies is expected to assist the growth of the segment during the forecast period.

Market Trends:

Various studies are focused on developing alternatives to drugs in the treatment of neuropathic pain. For instance, in March 2020, researchers at the Autonomous University of the State of Hidalgo, Mexico, reported that pomegranate and secondary metabolites can be effective in the treatment of inflammatory, nociceptive, and neuropathic pain.

The market is witnessing adoption of combination therapies as an effective approach in the treatment of neuropathic pain. For instance, in March 2020, researchers from Universitat Autnoma de Barcelona, Spain, reported that NeuroHeal a combination of two repurposed drugs: Acamprosate and Ribavirin reduces the appearance of neuropathic pain in peripheral nerve injury.

Competitive Landscape:

Major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., CODA Biotherapeutics, Inc., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, Neuroheal Biomedicals, S.L., and Depomed, Inc.

Key Developments:

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in May 2020, CODA Biotherapeutics, Inc. collaborated with the Facial Pain Research Foundation for R&D of new therapies for trigeminal neuralgia and related neuropathic pain using CODAs chemogenetic gene therapy platform.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3656

Taxonomy (Scope, segments)

See more here:
Neuropathic Pain Market to reach US$ 9,862.3 Million globally by 2027 Coherent Market Insights - GlobeNewswire

BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the novel drug candidate (NRD135S.E1) for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) to evaluate NRD135S.E1 in a Phase 2 study.

Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019. The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients experiencing neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months.

Submitting this IND is an important next step in the clinical development of NRD135S.E1 for the treatment of PDPN and we are moving rapidly to potentially address a global unmet medical need, said Sara Mangialaio, M.D., Ph.D., CMO and Head of R&D at Novaremed. We look forward to launching this Phase 2 study as soon as possible. This study will provide further important information about the safety and efficacy of NRD135S.E1, which was very well tolerated and induced a clinically relevant reduction in pain in the previous Phase 2 Proof of Concept study of 3-week duration.

The company is currently in discussions with potential investors to raise the necessary funding to support the conduct of the proposed Phase 2 study, as well as prepare for further late-stage development activities of NRD135S.E1.

Safe and effective therapies are critical to provide patients and physicians with treatment alternatives for PDPN, said Subhasis Roy, M.Com, MBA, CEO/COO of Novaremed. The next steps announced today for NRD135S.E1 highlight the result of Novaremeds many years of pursuit to move a novel non-opioid drug against PDPN as rapidly as possible.

Novaremed also announced today the appointment of three new members to the companys board of directors, effective May 14, 2020. Joining the board are Thomas Meier, Ph.D., Benyamin Sidon and Eliahu Kaplan, M.D. These appointments bring Novaremeds total board membership to six.

Dr. Thomas Meier is a dynamic life sciences entrepreneur who established Santhera Pharmaceuticals (SIX Exchange: SANN) as a successful Biotech/Specialty Pharma company in Switzerland. In the past 20 years he held executive positions (CSO and CEO) and successfully supported or executed mergers, acquisitions, product licensing and turn-around situations. Since 2017 he is member of Santheras Board of Directors. He holds a Ph.D. in Biology from the University of Basel and carried out post-doctoral training at the University of Colorado Health Sciences Center (USA) and Biozentrum, University of Basel, where he became group leader and lecturer in neurosciences before joining the industry. He is an internationally recognized scientist with track record in clinical research of orphan diseases (neuromuscular, neuro-ophthalmology). In 2007, he received the BioValley Basel Award for his outstanding contributions to the life sciences in the area.

Mr. Benyanin Sidon is an Investment Advisor at Gefen Biomed Investments, an Israeli public company, investing in Israeli startups with disruptive technologies. He has been active in fund raising and portfolio management activities in Israel over the last three decades. He sits on the board of directors of several portfolio companies of Gefen in Israel and abroad. He has a B.A. in Economics from Tel Aviv University, Israel.

Dr. Eliahu Kaplan is the founder, former board member and CEO of Novaremed Ltd as well as former CEO and Chief Innovator of Novaremed AG. He has more than 30 years of experience in the pharmaceutical industry particularly in oncology drug development. He worked at Farmitalia Carlo Erba in Milan, Italy as Director of Oncology Corporate Medical Department, as Medical Director in Freiburg, Germany as well as in Israel. In addition, between 1994 and 1998, he founded Seneb-Pharma, a consulting firm to consult in the field of R&D of drugs and medical products. Between 2005 and 2006 he was Medical Director (part-time) at Oridion BreathID in Israel.

We are excited to welcome Thomas, Benny and Eli to our board of directors. They bring decades of leadership in drug development and in business, that are vital to our future operations and strategy, said Isaac Kobrin, M.D., Chairman of the Board of Novaremed.

Notes to the Editor:

About Novaremed

Novaremed Ltd, a wholly owned subsidiary of Novaremed AG was founded in 2008 in Israel and Novaremed AG was founded in 2017 in Switzerland. Novaremed Ltd is developing NRD135S.E1, an orally active non-opioid small molecule with a novel mechanism of action against PDPN. In a Phase 2 Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2 study in PDPN. For more information, visit http://www.novaremed.com.

See the original post here:
Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also...

DUBLIN--(BUSINESS WIRE)--The "Global Neuropathy Pain Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The neuropathy pain treatment market is poised to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The market is driven by the presence of large patient pool and focus toward the development of novel therapeutics for postherpetic neuralgia.This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

The neuropathy pain treatment market analysis includes type segment and geographic landscape.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The neuropathy pain treatment market covers the following areas:

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuropathy pain treatment market vendors that include Abbott Laboratories, Assertio Therapeutics Inc. , AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi. Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by drug class

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/4n7ghp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

More here:
World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer -...

A Lesser-Known Chemotherapy Side Effect

The well-known side effects of chemotherapy can usually be dealt with fairly effectively for many women, though we empathize with anyone having to go through chemo. Two of the most common chemo side effects, nausea and hair loss, can both be managed with available treatments. The same is true of another, lesser-known side effect of chemotherapy, called neuropathy.

Neuropathy is the medical term for numbness or tingling in the fingers or toes, caused by powerful chemotherapy drugs damaging the peripheral nerves. Women receiving ovarian cancer chemotherapy with the taxane (Taxol) or platinum group of drugs are particularly susceptible to this side effect of treatment.

Fortunately oncologists are usually well-versed in this side effect, and take steps to try and minimize the problem during treatment. We usually assess for the degree of neuropathy prior to every dose of chemotherapy, says Dr. Manojkumar Bupathi, a medical oncologist at Rocky Mountain Cancer Center in Littleton, Colorado. In the event that neuropathy is getting worse, we can adjust the doses or delay treatments. We can also switch a patients drugs if it becomes an ongoing issue.

Symptoms

In addition to the numbness and tingling sensations that are characteristic of neuropathy, some patients may also experience:

Treatment

Patients can try several different approaches to dealing with neuropathy. We usually ask patients to use things like ice packs or protective gloves to try and mitigate the neuropathy, says Dr. Bupathi.

When simple treatments like this dont work, patients may want to consult a neurologist who can help treat the condition with a variety of different medications, including:

Prognosis

Most neuropathy goes away and improves over time, but sometimes it can take upwards of a year before it gets better, says Dr. Bupathi. While neuropathy may be permanent, Dr. Bupathi says that it usually persists as numbness or tingling, and isnt usually debilitating, where someone isnt able to walk or do basic things like buttoning a shirt or lifting a pen off a countertop.

If youre undergoing chemotherapy and start to experience symptomsnumbness, tingling, pain or weakness in the hands and feetmake sure to let your oncologist know so that you can take steps to relieve the symptoms and prevent permanent nerve damage.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Manojkumar Bupathi is a medical oncologist with Rocky Mountain Cancer Centers. Read More

Neuropathy is the medical term for numbness or tingling in the fingers or toes, caused by powerful chemotherapy drugs damaging the peripheral nerves. Women receiving ovarian cancer chemotherapy with the taxane (Taxol) or platinum group of drugs are particularly susceptible to this side effect of treatment.

Symptoms

In addition to the numbness and tingling sensations that are characteristic of neuropathy, some patients may also experience:

Treatment

Patients can try several different approaches to dealing with neuropathy. We usually ask patients to use things like ice packs or protective gloves to try and mitigate the neuropathy, says Dr. Bupathi.

When simple treatments like this dont work, patients may want to consult a neurologist who can help treat the condition with a variety of different medications, including:

Prognosis

Most neuropathy goes away and improves over time, but sometimes it can take upwards of a year before it gets better, says Dr. Bupathi. While neuropathy may be permanent, Dr. Bupathi says that it usually persists as numbness or tingling, and isnt usually debilitating, where someone isnt able to walk or do basic things like buttoning a shirt or lifting a pen off a countertop.

If youre undergoing chemotherapy and start to experience symptomsnumbness, tingling, pain or weakness in the hands and feetmake sure to let your oncologist know so that you can take steps to relieve the symptoms and prevent permanent nerve damage.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Manojkumar Bupathi is a medical oncologist with Rocky Mountain Cancer Centers. Read More

Originally posted here:
How Do You Deal With The Painful Tingling of Neuropathy? A Side Effect of Chemotherapy for Ovarian Cancer - SurvivorNet

This report studies the Chemotherapy Induced Peripheral Neuropathy Treatment Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Chemotherapy Induced Peripheral Neuropathy Treatment Market analysis segmented by companies, region, type and applications in the report.

Market Segment by Companies: Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma, and more

Request a Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=coleofduty&utm_medium=39

Chemotherapy Induced Peripheral Neuropathy Treatment Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Chemotherapy Induced Peripheral Neuropathy Treatment Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers:

Research Objectives:

Browse More Details @ https://www.reportsandmarkets.com/reports/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=coleofduty&utm_medium=39

The Chemotherapy Induced Peripheral Neuropathy Treatment Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents:

Key questions answered in this report:

Get Complete Report @ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=3323528&utm_source=coleofduty&utm_medium=39

About Us:

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serves our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Continue reading here:
Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth Analysis 2020-2026 with Market Share, Size, Trends, Revenue, CAGR and SWOT...

The report on the Chemotherapy Induced Peripheral Neuropathy Treatment market provides a birds eye view of the current proceeding within the Chemotherapy Induced Peripheral Neuropathy Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Chemotherapy Induced Peripheral Neuropathy Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Chemotherapy Induced Peripheral Neuropathy Treatment market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Chemotherapy Induced Peripheral Neuropathy Treatment market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Chemotherapy Induced Peripheral Neuropathy Treatment market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2638040&source=atm

The major players profiled in this Chemotherapy Induced Peripheral Neuropathy Treatment market report include:

Segment by Type, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented intoCalcium Channel 2-delta LigandsAntidepressantsOpioidsOthers

Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented intoPlatinum AgentsTaxanesVinca AlkaloidsOthers

Regional and Country-level AnalysisThe Chemotherapy Induced Peripheral Neuropathy Treatment market is analysed and market size information is provided by regions (countries).The key regions covered in the Chemotherapy Induced Peripheral Neuropathy Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Chemotherapy Induced Peripheral Neuropathy Treatment Market Share AnalysisChemotherapy Induced Peripheral Neuropathy Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chemotherapy Induced Peripheral Neuropathy Treatment business, the date to enter into the Chemotherapy Induced Peripheral Neuropathy Treatment market, Chemotherapy Induced Peripheral Neuropathy Treatment product introduction, recent developments, etc.The major vendors covered:Aptinyx IncAsahi Kasei Pharma CorpRegenacy PharmaceuticalsMAKScientific LLCMetys Pharmaceuticals AGNemus Bioscience IncPledPharmaSova Pharmaceuticals IncDermaXon LLCKineta IncKrenitsky Pharmaceuticals IncPeriphaGenApexian PharmaWinSanTorSolasia Pharma K.K.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2638040&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2638040&source=atm

Read the original:
COVID-19 impact: Chemotherapy Induced Peripheral Neuropathy Treatment Market : In-depth Study on Industry Size and Analysis on Emerging Growth Factors...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 aims to target the major concepts related to market growth, major types, and various end users applicable, regional analysis, productivity structure, current market situation. The market report is a proficient and deep analysis of the present situation and challenges. The report offers analysis with regards to the past and current market situation of the global Chemotherapy Induced Peripheral Neuropathy Treatment market. The report highlights all introducing income segmentation and also a firm sketch of the top players. It comprises streamlined financial data obtained from various research sources. The report analyzes the market players, sub-segments and sections, product category, and major improvements in the market.

Overview of The Report:

Top players are examined for revenue areas manufacturing, market rivalry, capacity, sales (value), moderate price, fabricating base supply and market share, and product types. The report also computes the limits and strong points of the players. The report studies key opportunities in the market and segmentation of market size, by volume and value, on the basis of application type and geography. The report focuses on innovative trends, implementing reasonable pricing stats in the competitive market. The overall description of the global Chemotherapy Induced Peripheral Neuropathy Treatment market will assist our viewers to comprehend the market in the best way. It sheds light on the industry parameters by accessing the market growth, consumption volume, the upcoming market trends, and the different prices variation for the forecast year from 2020 to 2026.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/41488

The report covers a number of the players in the market, including: Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma,

Segmentation by product type and analysis of the market: Calcium Channel _2-delta Ligands, Antidepressants, Opioids, Others

Segmentation by application and analysis of the market: Platinum Agents, Taxanes, Vinca Alkaloids, Others

The scope of the report covers market eventualities to a comparative rating between major players, price, and profit of the required market regions. This report covers North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). It focuses on the foremost and the progressing countries from every region in detail.

The report represents the ongoing marketing trends that are faced by the market competitors, the ups, and downs in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. Subsequently, it discovers the worlds main Chemotherapy Induced Peripheral Neuropathy Treatment industry market requirements, for example, demand, distribution, profit, production, capacity, and promote growth speed and prediction, etc. The company further divides even the economy, by state also from application/type for its landscape analysis.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/41488/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026

Major Points From TOC:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

More here:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Company Profiles, Key Strategic Moves and Developments, Operating Business...

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

Request to Sample report @https://www.persistencemarketresearch.com/samples/23077

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

Request For TOC @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

Regional analysis includes

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

For in-depth competitive analysis, buy[emailprotected]https://www.persistencemarketresearch.com/checkout/23077

Some of the market players operating in the ischemic optic neuropathy treatment market include ,

The report covers exhaustive analysis on:

Read the original here:
Ischemic Optic Neuropathy Treatment Market Upcoming Trends, Incredible Possibilities, Business Opportunities ,Regional Outlook and Forecast 2018-2026...

Fact.MR has adopted multi-disciplinary approach to shed light on the evolution of the global Diabetic Neuropathy market during the historical period of 2014 2019. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2020, and key prospects over the forecast period 2020 2025.The Diabetic Neuropathy market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global Diabetic Neuropathy market. Further, the presented study offers accurate insights pertaining to the different segments of the global Diabetic Neuropathy market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

The global diabetic neuropathy is anticipated to surge at a CAGR of 5.6% during the forecast period (2020-2025). Extensive rounds of primary and a comprehensive secondary research have been leveraged by the analysts at Fact.MR to arrive at various estimations and projections of the Diabetic Neuropathy market, both at global and regional levels. The analysts have used numerous industry-wide prominent business intelligence tools to consolidate facts, figures, and market data into revenue estimations and projections in theDiabetic Neuropathy market.

After reading the Diabetic Neuropathy market report, readers get insight into:

Request for Sample Report with Statistical Info @https://www.factmr.com/connectus/sample?flag=S&rep_id=4698

The Diabetic Neuropathy market report offers assessment of prevailing opportunities in various regions and evaluates their shares of revenue by the end of different years of the assessment period. Key regions covered comprise:

The evaluation of the competitive landscape in the Diabetic Neuropathy market covers the profile of the following top players:

Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline Plc.,Lupin Limited, Astellas Pharma Inc., Pfizer, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc.

To expand the understanding of opportunities in the global Diabetic Neuropathy market report looks at close quarters into the opportunities and new avenues in following key segments:

In addition to understanding the demand patterns of various Distribution Channel, the report on the Diabetic Neuropathy market also enumerates trends expected to attract investments by other various associated industries.

On the basis of Disorder types, the Diabetic Neuropathy market report offers insight into major adoption trends for the following segments:

By Treatment Type,

Peripheral Neuropathy

Drugs:

Analgesic:

Topical:

Opioid:

NSAIDs:

Antidepressants:

TCAs:

SNRIs:

SSRIs:

Anticonvulsant Drugs:

Other Drugs

Radiotherapy:

Physiotherapy

The global Diabetic Neuropathy market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

For More Detailed Information about Methodology @https://www.factmr.com/connectus/sample?flag=RM&rep_id=4698

Some important questions that the Diabetic Neuropathy market report tries to answer exhaustively are:

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; thats why we publish multi-industry global, regional, and country-specific research reports.

Media Release:https://www.factmr.com/media-release/1445/global-diabetic-neuropathy-market

Read more:
Diabetic Neuropathy Market Demand Surges Owing to Increasing Production Associated With Covid-19, Concludes Fact.MR - The Cloud Tribune

Shuhei Nakanishi,1 Hidenori Hirukawa,1 Masashi Shimoda,1 Fuminori Tatsumi,1 Kenji Kohara,1 Atsushi Obata,1 Seizo Okauchi,1 Junpei Sanada,1 Yoshiro Fushimi,1 Akiko Mashiko,1 Tomoatsu Mune,1 Kohei Kaku,2 Hideaki Kaneto1

1Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Okayama, Japan; 2Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan

Correspondence: Shuhei Nakanishi Email n-shuhei@umin.net

Introduction: This study aimed to examine the association between severity of diabetic neuropathy and weight loss during hospitalization in overweight participants with type 2 diabetes.Patients and Methods: Participants of this study comprised 193 patients who were hospitalized for type 2 diabetes treatment. The participants were divided into two groups in the study, based on whether or not reduction of bodyweight was at least 3% during hospitalization. Using Cox models, the association between severity of neuropathy and effectiveness of weight loss under a controlled diet was analyzed. Autonomic neuropathy was assessed on patient admission by R-R interval, as measured in an electrocardiogram (CVRR), and sensory neuropathy was assessed using both 128-Hz tuning-fork vibration and Achilles tendon reflex (ATR).Results: The adjusted hazard ratio for weight loss of at least 3% for CVRR was 1.17 (95% confidence interval 1.07 1.28, P=0.0006) and for vibration time 1.93 (1.01 3.68, P=0.045). After dividing CVRR and vibration time into tertiles based on participant number, the adjusted hazard ratio for the high tertile of CVRR was 2.17 (1.29 3.62, P=0.003), and for the long tertile of vibration time 1.84 (1.10 3.08, P=0.02), compared with the low and short tertiles, respectively. No association was detected between ATR category and weight loss.Conclusion: Severity of diabetic neuropathy was found to be a determinant in weight loss under a caloric restriction regimen for patients with type 2 diabetes. The results of the study suggest that the peripheral nervous system is involved in responses to medical intervention for treatment for type 2 diabetes including bodyweight management.

Keywords: diabetic neuropathy, weight loss, R-R interval as measured in an electrocardiogram, type 2 diabetes

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Association Between Severity of Diabetic Neuropathy and Success in Wei | DMSO - Dove Medical Press

Krenitsky Pharmaceuticals Inc

Moreover, the Chemotherapy Induced Peripheral Neuropathy Treatment report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Chemotherapy Induced Peripheral Neuropathy Treatment market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Chemotherapy Induced Peripheral Neuropathy Treatment market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=259478&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Chemotherapy Induced Peripheral Neuropathy Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Deployment Model

5.1 Overview

6 Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Solution

6.1 Overview

7 Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Vertical

7.1 Overview

8 Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=259478&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends, Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth, Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast, Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Infusion Pump Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Injection Pen Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Arbor Pharmaceuticals

Moreover, the Neuropathy Pain Treatment report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Neuropathy Pain Treatment market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Neuropathy Pain Treatment market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275286&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Neuropathy Pain Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Neuropathy Pain Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Neuropathy Pain Treatment Market, By Deployment Model

5.1 Overview

6 Neuropathy Pain Treatment Market, By Solution

6.1 Overview

7 Neuropathy Pain Treatment Market, By Vertical

7.1 Overview

8 Neuropathy Pain Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Neuropathy Pain Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=275286&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Neuropathy Pain Treatment Market Size, Neuropathy Pain Treatment Market Trends, Neuropathy Pain Treatment Market Growth, Neuropathy Pain Treatment Market Forecast, Neuropathy Pain Treatment Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

High Voltage Surge Arrester Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

High Voltage Wiring Connectors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the article here:
Neuropathy Pain Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Ever seen an advertisement for something called diabetic socks, and wondered what in the world that was about? Can socks get diabetes? Can other items of clothing be diabetic? What does diabetes have to do with feet anyway?

Footcare certainly isn't the first thing that comes to mind when one thinks about diabetes, but the fact is that diabetics are at a high risk of foot injuries and infections due to the potential damage high blood sugar levels can do to the nervous and circulatory systems.

A variety of other factors can also pose a risk to diabetics and their feet.

Feet must be washed and thoroughly dried regularly to prevent fungal infections like athletes' feet from excess moisture. Washing your feet with warm, soapy water each day will help prevent bacteria buildup and infection. Applying talcum powder between toes afterward can dry out those areas and reduce the chance of athletes foot and other fungal infections.

Extreme temperatures are also a hazard. As tempting as it may be, dont put your feet up in front of your campfire. You should also wear closed shoes when walking on hot sand or pavement and always apply sunscreen to your feet when theyre exposed to the sun. If you have nerve damage in your feet, you may not notice a burn until its severe, so its best to prevent it altogether.

Cold feet can also be related to restricted blood flow, so keep them warm by sleeping with socks on in the winter and wearing warm, waterproof shoes in bad weather.

While diligent daily care is the best way to keep feet healthy, diabetic socks are a great tool to help you out.

Diabetic socks, are socks specially designed to prevent the development of foot problems among those living with diabetes. Their features are engineered to address all the aforementioned issues to help you keep your feet healthy.

These socks are usually made of a material that wicks away moisture, like that found in exercise clothing, so that the feet stay dry. Some brands even have antimicrobial features in their fabric to help prevent bacteria and fungal growth. In colder temperatures, these socks will keep your feet warm, ensuring good circulation.

These socks are also seamless, so you dont have to worry about pesky rubbing producing blisters. In someone with neuropathy or chronic high blood sugar, something as small as a blister can ultimately turn into an ulcer. Special padding in sensitive areas also helps to prevent injuries like this.

In many cases, diabetic socks have white soles. This can alert the wearer if they have any sort of foot wound because the drainage of blood or other fluid will be visible from outside the sock.

There are a variety of diabetic socks available, with different features and advantages to suit each individuals needs. Consider which are best for you or get a variety for different times of the year and different activity levels.

In general, diabetic socks serve one or more of three purposes: they keep your feet dry, they keep temperature steady, and they prevent abrasions. All will do each of these to some degree, but you can choose which to prioritize in your choices.

While most diabetic socks have some sort of moisture-wicking technology, be sure to look for this specifically if you are very active or have a physically demanding job. These materials pull moisture away from the feet to help to evaporate the sweat, reducing the risk of fungus and infections. They also help to cut down on odor.

Copper-infused socks are made with copper-infused yarn and also have antifungal properties and anti-odor protection.

Padded acrylic socks are ideal for those who exercise often because they keep feet dry and help cushion them to reduce the risk of any foot injury.

You can also find heavily padded or gel-padded socks if you are in need of this additional cushioning.

The yarns that make up your socks can also make a huge difference in the health of your feet. While most diabetic socks are made from soft yarns like wool and bamboo, you can also find those specially made to reduce friction that causes blisters.

If youre really looking to maximize the benefits of your socks, consider new smart socks, which have embedded sensors that alert you of foot temperature changes that might be signs of friction that causes blisters to form. These socks need to be replaced regularly but are a great option for those without much feeling in their feet.

Whatever type of sock you choose, be sure to change and wash them regularly and replace them at the first sign of wear and tear, as holes or pilling can themselves cause injury.

Its important to remember that while diabetic socks are a great tool for the prevention of foot problems, you should always see your doctor if youve already developed an issue.

Slow-healing wounds, unusual odor, and continuous pain in legs are all signs that something is wrong and you should check in with your doctor. Also, keep an eye out for changes in the color or shape of your feet, and ask your doctor to do a foot check-up at your next visit to make sure theyre healthy. Diligent care is the best way to prevent foot problems from developing.

Read the original:
What are Diabetic Socks and Why Might You Need Them? - The Jerusalem Post